Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 47,000
Avg Vol 31,380
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 68%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infan...

Industry: Biotechnology
Sector: Healthcare
Phone: 215 488 9300
Address:
2600 Kelly Road, Suite 100, Warrington, United States
Latest News on WINTW
No data available.